Login to Your Account

U.S. Patent Disclosures

Friday, January 18, 2013
• Lithera Inc., of San Diego, was issued a notice of allowance for its U.S. patent application, related to LIPO-202 (Salmeterol Xinafoate for Injection). LIPO-202 is being developed for selective, nonablative, local fat reduction.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription